PolyActiva announced the appointment of experienced ophthalmic industry expert, Tracy Valorie, as a new member to the company’s Board of Directors.
Ms. Valorie is recognized in the industry for her success in building and leading high performing teams and for her ability to lead commercialization of innovative products in ophthalmology. She was previously the Senior Vice President and General Manager of the US Pharmaceutical and Surgical Business of Bausch + Lomb. Prior to joining Bausch + Lomb, Ms. Valorie was the Commercial Lead of Ophthalmology at Pfizer in New York.
“Ms Valorie’s extensive experience in both development of new products for the treatment of ophthalmic conditions and their ultimate commercialization will be a significant asset to the team,” PolyActiva’s CEO, Russell Tait, BPharm, PhD, said in a company news release. “We are delighted to have Ms. Valorie join. PolyActiva will benefit immensely from the diverse sector experience and strategic input she brings to the company.”
“She has joined PolyActiva just as we advance our first two assets into the clinic and seek to expand our strategic and technical capabilities. Our ultimate goal is to become a premier company in ophthalmic drug delivery,” Dr. Tait said.
Ms. Valorie has spent more than half of her career dedicated to ophthalmology and is dedicated to advancing the category. She has previously held board membership seats at The Glaucoma Foundation and the ARVO Foundation for Eye Research. She is also a former board member of and current advisor to Ophthalmic World Leaders (OWL), Advancing Diversity in Leadership, which aims to promote and develop diverse leadership to advance Ophthalmic Innovation and Patient Care.
“I am honoured to join PolyActiva’s Board as the company moves into this new phase of growth,” said Ms. Valorie. “The company’s technology has unique capabilities that have the potential to serve patients across a variety of ophthalmic disorders.”
“The implants provide sustained treatment that can be tailored for the indication. The two programs in clinical development, one for glaucoma and one for prevention of infection demonstrate the flexibility of the platform and give confidence in use of the technology for other disease categories,” continued Ms Valorie. “I look forward to working closely with the board and management to realize the full potential of this technology.”